Long term treatment of HIV-infection with TMC278
US10953009B2 · kind B2 · utility
1Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2007 |
| Grant date | Mar 23, 2021 |
| Priority date | — |
| Expiry date | Nov 27, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.